Acta dermato-venereologica最新文献_第10页

AI-assisted Total Body Dermoscopic Evaluation of Changes in Melanocytic Nevi during Pregnancy: A Prospective, Comparative Study of 2,799 Nevi. 人工智能辅助全身皮肤镜评估妊娠期间黑素细胞痣的变化：一项2799例痣的前瞻性比较研究。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-01-03 DOI: 10.2340/actadv.v105.41025

Jelissa K Peter, Fabrice Helfenstein, Sara E Cerminara, Julia-Tatjana Maul, Mara L Zehnder, Dagmar Jamiolkowski, Elisabeth Roider, Beda Mühleisen, Irene Hösli, Alexander A Navarini, Lara V Maul

{"title":"AI-assisted Total Body Dermoscopic Evaluation of Changes in Melanocytic Nevi during Pregnancy: A Prospective, Comparative Study of 2,799 Nevi.","authors":"Jelissa K Peter, Fabrice Helfenstein, Sara E Cerminara, Julia-Tatjana Maul, Mara L Zehnder, Dagmar Jamiolkowski, Elisabeth Roider, Beda Mühleisen, Irene Hösli, Alexander A Navarini, Lara V Maul","doi":"10.2340/actadv.v105.41025","DOIUrl":"10.2340/actadv.v105.41025","url":null,"abstract":"Pregnancy-associated changes in melanocytic nevi (MN), apart from size increase on the trunk, remain a topic of debate. We conducted the first prospective study to investigate dermoscopic changes in MN comparing pregnant with non-pregnant women on all body parts using a market-approved convolutional neural network (CNN). We included 25 pregnant and 25 non-pregnant women from Basel, Switzerland, who underwent standard skin cancer screenings and whose MN > 2 mm were digitally recorded and analysed by a CNN. Pregnant women were examined three times: in the first and third trimester and 8-12 weeks postpartum; non-pregnant women twice in an interval of 17-21 weeks. We analysed 2,799 MN. In pregnant women, diameter[p < 0.001], area[p < 0.001], number of colours [p = 0.009], shape asymmetry[p = 0.005] and border sharpness[p = 0.006] (inversely proportional value) increased while ellipseness [p < 0.001] decreased from first trimester to postpartum. Changes occurred mainly during the third trimester to postpartum. Compared to non-pregnant women (only first to third trimester) MN on the upper extremities of pregnant women increased in area[p = 0.011] and diameter[p = 0.025] and decreased in ellipseness[p = 0.037]. MN on the lower extremities increased in area[p = 0.044] and MN on the back increased in colour asymmetry[p = 0.022].","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv41025"},"PeriodicalIF":3.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing the Comorbidity Cycle Between Psoriasis and Addiction Based on ICD Coding in the Stockholm Psoriasis Cohort. 基于ICD编码的斯德哥尔摩银屑病队列中银屑病和成瘾的共病周期评估

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-01-03 DOI: 10.2340/actadv.v105.41221

Hannah Wecker, Axel Svedbom, Fabio Sánchez Orrego, Stefanie Ziehfreund, Mona Ståhle, Alexander Zink

{"title":"Assessing the Comorbidity Cycle Between Psoriasis and Addiction Based on ICD Coding in the Stockholm Psoriasis Cohort.","authors":"Hannah Wecker, Axel Svedbom, Fabio Sánchez Orrego, Stefanie Ziehfreund, Mona Ståhle, Alexander Zink","doi":"10.2340/actadv.v105.41221","DOIUrl":"10.2340/actadv.v105.41221","url":null,"abstract":"The comorbidity cycle between psoriasis and addictions remains unclear. The study aimed to investigate the cumulative incidence of addictions in psoriasis patients and controls in the Stockholm Psoriasis Cohort (SPC). The SPC is an observational cohort study that enrolled psoriasis patients between 2001 and 2005 and matched controls using the Swedish Total Population Register. Data were complemented by medical records from 1987-2013, focusing on 11 addiction diagnoses and the date of their assignment. Overall, 4,545 individuals (56.4% female; median age: 40) were included: 722 psoriasis patients and 3,823 controls. Patients showed 1.4 times (95% confidence interval: 0.98-1.98) higher odds of addiction diagnosis than controls. Alcohol dependency was the most common addiction diagnosis (78.2%), which was more frequent in patients than in controls (94.3% vs 73.6%, p = 0.009). Furthermore, patients showed 4.3 times (1.85-11.56) higher odds of receiving an addiction diagnosis after their initial psoriasis diagnosis than before. Results showed a tendency towards a higher risk of addiction in psoriasis patients, suggesting potential psoriasis-triggered addictive behaviour. Nevertheless, both substance abuse triggering psoriasis and chronic psoriasis inflammation triggering addictions have to be considered. In both cases, addictive behaviour needs to be addressed in psoriasis healthcare as a driver for poor disease outcome and comorbidities.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv41221"},"PeriodicalIF":3.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital. 接受免疫检查点抑制剂的肿瘤患者皮肤免疫相关不良事件与总生存期和无进展生存期的关联：一项西班牙三级医院189例患者的前瞻性研究

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2025-01-03 DOI: 10.2340/actadv.v105.42023

Gloria Juan-Carpena, Natividad Martínez Banaclocha, Juan Carlos Palazón Cabanes, Maria Niveiro-de Jaime, Isabel Betlloch Mas, Mar Blanes-Martínez

{"title":"Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital.","authors":"Gloria Juan-Carpena, Natividad Martínez Banaclocha, Juan Carlos Palazón Cabanes, Maria Niveiro-de Jaime, Isabel Betlloch Mas, Mar Blanes-Martínez","doi":"10.2340/actadv.v105.42023","DOIUrl":"10.2340/actadv.v105.42023","url":null,"abstract":"Cutaneous immune-related adverse events (cirAEs) may be associated with tumoral response and survival in patients using immune checkpoint inhibitors, but this relationship remains unclear because previous reports on the topic have various limitations. The purpose of this study was to examine the association of cirAEs with overall survival and progression-free survival in patients starting immune checkpoint inhibitors. A prospective observational study was conducted in a Spanish tertiary care hospital, including participants between March 2020 and May 2022. The statistical analysis involved the Kaplan-Meier method, log-rank test, and multivariable Cox proportional hazards regression models. At total of 189 patients were included, of whom 82 (43.4%) presented cirAEs. Most participants (56.6%) were diagnosed with non-small cell lung cancer (NSCLC). Mortality and progression rates were lower in patients with vs without cirAEs (p < 0.0001). Cox models showed that cirAEs were a protective factor for overall survival (adjusted HR 0.50; p < 0.0001) and progression-free survival (adjusted HR 0.54; p = 0.001) independently of cancer type, tumour stage or immune checkpoint inhibitor category. There were similar results for extracutaneous irAEs. A limitation was the single-centre design. CirAE occurrence is positively associated with longer survival and less cancer progression among immune checkpoint inhibitor recipients independently of other factors.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42023"},"PeriodicalIF":3.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142918877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An International Examination of Skin Concerns Impacting Self-Confidence Among 5,138 Males. 一项对5138名男性皮肤问题影响自信的国际调查。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-13 DOI: 10.2340/actadv.v104.42016

Frederic Flament, Aurelie Maudet, Caroline Delaunay, David Amar, Muriel Bayer-Vanmoen, Audrey Imbert Legrain, Charles Taieb, Charbel Skayem, Laurence Lebarbanchon

引用次数: 0

Impact of Skin Type and Sensitivity on Dermatological Concerns and Self-confidence: Insights from an International Study of 14,317 Women. 皮肤类型和敏感性对皮肤病学关注和自信的影响：来自14,317名女性的国际研究的见解。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-13 DOI: 10.2340/actadv.v104.42424

Frederic Flament, Aurelie Maudet, Caroline Delauney, David Amar, Muriel Bayer-Vanmoen, Audrey Imbert Legrain, Charles Taieb, Charbel Skayem, Laurence Lebarbanchon

引用次数: 0

Effect of Therapeutic Patient Education in Adults with Atopic Dermatitis: Analysis of Efficacy and Treatment Needs. 治疗性患者教育对成人特应性皮炎的疗效及治疗需求分析。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-12 DOI: 10.2340/actadv.v104.41184

Marine Fargeas, Mathieu Fauvernier, Marie Tauber, Julien Seneschal, Virginie Verdu, Magali Bourrel Bouttaz, Florence Hacard, Anne-Sophie Darrigade, Audrey Nosbaum

{"title":"Effect of Therapeutic Patient Education in Adults with Atopic Dermatitis: Analysis of Efficacy and Treatment Needs.","authors":"Marine Fargeas, Mathieu Fauvernier, Marie Tauber, Julien Seneschal, Virginie Verdu, Magali Bourrel Bouttaz, Florence Hacard, Anne-Sophie Darrigade, Audrey Nosbaum","doi":"10.2340/actadv.v104.41184","DOIUrl":"10.2340/actadv.v104.41184","url":null,"abstract":"In the era of biological treatments and small molecules, this study assessed therapeutic patient education (TPE) in managing adult atopic dermatitis (AD), focusing on disease severity, quality of life, and the use of systemic treatments. This multicentre study included 260 adult AD patients, with 184 undergoing a full TPE programme and 76 control patients. Evaluations included disease severity, quality of life (DLQI), and systemic treatment use. The primary goal was to measure AD improvement, with secondary goals assessing DLQI score changes and systemic treatment use. AD severity improved in 64.7% of TPE patients vs 45.7% of controls (p = 0.008). The mean DLQI score dropped by 5.7 points in the TPE group vs 2.4 points in controls (p = 0.006). Additionally, 69.8% of TPE patients had a DLQI score ≤ 4/30 compared with 50% of controls (p = 0.025). Regarding therapeutics, 83.6% of patients naive to systemic treatment at inclusion were maintained exclusively under topical treatment vs 21.7% in the control group. The likelihood of needing systemic treatment was 66% in controls vs 6% in the TPE group. TPE enhances AD severity and quality of life, ensures better disease control, and reduces systemic treatment use, highlighting its importance in managing adult AD.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"104 ","pages":"adv41184"},"PeriodicalIF":3.5,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study. Tebentafusp在转移性葡萄膜黑色素瘤中的疗效和耐受性：一项真实的回顾性多中心研究。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-12 DOI: 10.2340/actadv.v104.41297

Lucille Vitek, Thomas Goronflot, Caroline Dutriaux, Antoine Deleuze, Yannick Le Corre, Anne-Bénédicte Duval-Modeste, Cécile Fresnard, Géraldine Jeudy, Anouck Lamoureux, Caroline Gaudy-Marqueste, Delphine Legoupil, Barouyr Baroudjian, Jean-Matthieu L'Orphelin, Lucie Peuvrel, Amir Khammari, Laurent Mortier, Gaëlle Quereux

{"title":"Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.","authors":"Lucille Vitek, Thomas Goronflot, Caroline Dutriaux, Antoine Deleuze, Yannick Le Corre, Anne-Bénédicte Duval-Modeste, Cécile Fresnard, Géraldine Jeudy, Anouck Lamoureux, Caroline Gaudy-Marqueste, Delphine Legoupil, Barouyr Baroudjian, Jean-Matthieu L'Orphelin, Lucie Peuvrel, Amir Khammari, Laurent Mortier, Gaëlle Quereux","doi":"10.2340/actadv.v104.41297","DOIUrl":"10.2340/actadv.v104.41297","url":null,"abstract":"Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp's real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"104 ","pages":"adv41297"},"PeriodicalIF":3.5,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Varicella-zoster Virus Infections in Patients with Hospital-diagnosed Atopic Dermatitis. 医院诊断的特应性皮炎患者的水痘-带状疱疹病毒感染

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-12 DOI: 10.2340/actadv.v104.42326

Sigrun A J Schmidt, Eskild Kristiansen, Henrik T Sørensen, Christian Vestergaard, Mette S Deleuran

引用次数: 0

Epidermolysis Bullosa Simplex due to a Novel BPAG1-e Homozygous Pathogenic Variant Revealed by Bullous Scabies. 大疱性疥疮中由BPAG1-e纯合致病变异引起的单纯大疱性表皮松解症。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-12 DOI: 10.2340/actadv.v104.40691

Nathalie Pironon, Anne Welfringer-Morin, Stéphanie Leclerc-Mercier, Emmanuelle Bourrat, Alain Hovnanian

引用次数: 0

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation. 厄洛替尼抑制表皮生长因子受体可减轻卡伐克罗诱导的皮肤炎症。

IF 3.5 4区医学

Acta dermato-venereologica Pub Date : 2024-12-09 DOI: 10.2340/actadv.v104.40975

Yujing Wang, Wenjie Huang, Haidong Jia, Qinglian Tang, Qingfei Yin, Yuanyuan Chen, Wumei Wang, Zhengyu Cao

{"title":"Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation.","authors":"Yujing Wang, Wenjie Huang, Haidong Jia, Qinglian Tang, Qingfei Yin, Yuanyuan Chen, Wumei Wang, Zhengyu Cao","doi":"10.2340/actadv.v104.40975","DOIUrl":"10.2340/actadv.v104.40975","url":null,"abstract":"Epidermal growth factor receptors (EGFRs) regulate the growth and repair process of epithelia, as well as carcinogenesis. Activation of TRPV3 by carvacrol stimulates skin inflammation and epidermal hyperplasia; the latter can be suppressed by EGFR inhibition. However, whether EGFR signalling is responsible for skin inflammation remains elusive. The current study investigated the effect of erlotinib, an EGFR inhibitor, on skin inflammation in a carvacrol-induced atopic dermatitis mouse model. It was observed that erlotinib significantly attenuated carvacrol-induced overexpression of proinflammatory cytokines and suppressed peripheral blood mononuclear cell recruitment in HaCaT keratinocytes. In addition, it was demonstrated that erlotinib suppressed carvacrol-induced Akt and NF-κB signalling pathways. Furthermore, inhibition of Akt and NF-κB signalling pathways also attenuated the carvacrol-induced keratinocyte proinflammatory response. Finally, it was demonstrated that erlotinib treatment alleviated carvacrol-induced dermatitis. These data demonstrate that erlotinib ameliorates skin inflammation by regulating Akt and NF-κB-mediated keratinocyte proinflammation, suggesting the therapeutic potential of erlotinib, a clinically used EGFR inhibitor, in skin inflammatory diseases.","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"104 ","pages":"adv40975"},"PeriodicalIF":3.5,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11653204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0